当前位置: X-MOL 学术J. Natl. Cancer Inst. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2018-02-22 , DOI: 10.1093/jnci/djy003
Naris Nilubol 1 , ZiQiang Yuan 2 , Giulio F Paciotti 3 , Lawrence Tamarkin 3 , Carmen Sanchez 2 , Kelli Gaskins 1 , Esther M Freedman 1 , Shugeng Cao 4 , Jielu Zhao 4 , David G I Kingston 4 , Steven K Libutti 2 , Electron Kebebew 1
Affiliation  

The advantages of nanomedicines include preferential delivery of the payload directly to tumor tissues. CYT-21625 is the novel, first-in-class gold nanomedicine designed to target tumor vasculature and cancer cells by specifically delivering recombinant human tumor necrosis factor alpha (rhTNF) and a paclitaxel prodrug.

中文翻译:

具有转移性甲状腺癌和胰腺神经内分泌肿瘤的小鼠的新型双重作用靶向纳米药物。

纳米药物的优点包括将有效载荷直接直接递送至肿瘤组织。CYT-21625是新颖,一流的金纳米药物,旨在通过特异性递送重组人肿瘤坏死因子α(rhTNF)和紫杉醇前药来靶向肿瘤脉管系统和癌细胞。
更新日期:2018-02-22
down
wechat
bug